Figure 6.

Relapse‐free survival of gastric cancer patients based on fibroblast growth factor receptor2⁺ (FGFR2⁺) circulating tumor cells (CTCs) and cytokeratin⁺ (CK⁺)/EpCAM⁺ CTCs. A, The Kaplan‐Meier survival curve indicates that the relapse‐free survival of patients with FGFR2⁺ CTCs was significantly (P < .001) poorer than that of the patients without FGFR2⁺ CTCs. B, No significant difference of the relapse‐free survival was found between CK⁺ EpCAM⁺ CTCs positive patients and CK⁺ EpCAM⁺ CTCs negative patients